A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease

NCTID	NCT06164730 (View at clinicaltrials.gov)
Description	VT-10201 is an Open-label, Phase 1b, Single-ascending Dose Study That Will Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia (HeFH) or Premature Coronary Artery Disease (CAD) Who Require Additional Lowering of LDL-C. VERVE-102 Uses Base-editing Technology Designed to Disrupt the Expression of the PCSK9 Gene in the Liver and Lower Circulating PCSK9 and LDL-C. This Study is Designed to Determine the Safety and Pharmacodynamic Profile of VERVE-102 in This Patient Population. (Show More)
Indication	Familial Hypercholesterolemia, Heterozygous
Compound Name	VERVE-102
Sponsor	Verve Therapeutics, Inc.
Funder Type	Industry
Status	Recruiting
Enrollment Count	36

No.of Trial Sites	3
Locations	Canada,United Kingdom

Has US IND	True
Recent Updates	First patient dosed in Phase 1b trial May 2024